StreetInsider.com News Articles

CorMedix (CRMD) PT Raised to $14 at RBC Capital

Fri, 14 Aug 2026 08:41:53 -0400

RBC Capital analyst Leonid Timashev raised the price target on CorMedix (NASDAQ: CRMD) to $14.00 (from $13.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on CorMedix (CRMD)

Fri, 14 Aug 2026 06:50:10 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $13.00 price target on CorMedix (NASDAQ: CRMD).

The analyst commented: "We believe CRMD’s current valuation largely reflects a bear-case outcome for DefenCath post-TDAPA, while giving the stock little credit for REZZAYO prophylaxis or additional DefenCath growth opportunities, creating a unique situation where we believe the risk reward is favorable going into a slowdown in Defencath revenue. The company has been proactive in getting out in front of the Defencath reimbursement issues over the next 12 months, bu providing 2026 and 2027 guidance. 2Q26 was another strong quarter for Defencath supporting our

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Today's Stocks in the News

Thu, 13 Aug 2026 12:27:19 -0400

DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts.

CorMedix Therapeutics: DefenCath Keeps the Cash Flow Story Accelerating

CorMedix Therapeutics (NASDAQ: CRMD) is entering the second half of 2026 with increasingly powerful commercial momentum. The company reported $101.9 million in second-quarter consolidated revenue, including $66.1 million from DefenCath and $35.8 million from its acquired Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. CorMedix also finished June with $256.7 million in

Form 10-Q CorMedix Inc. For: Jun 30

Thu, 13 Aug 2026 08:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26916922.html

Form 10-Q CorMedix Inc. For: Jun 30

Thu, 13 Aug 2026 08:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26916922.html

CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance

Thu, 13 Aug 2026 07:33:56 -0400

CorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.29, $0.06 better than the analyst estimate of $0.23. Revenue for the quarter came in at $101.93 million versus the consensus estimate of $95.62 million.
GUIDANCE:
CorMedix sees FY2026 revenue of $325-345 million, versus the consensus of $334.6 million.
For earnings history and earnings-related data on CorMedix (CRMD) click here.

CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance

Thu, 13 Aug 2026 07:33:56 -0400

CorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.29, $0.06 better than the analyst estimate of $0.23. Revenue for the quarter came in at $101.93 million versus the consensus estimate of $95.62 million.
GUIDANCE:
CorMedix sees FY2026 revenue of $325-345 million, versus the consensus of $334.6 million.
For earnings history and earnings-related data on CorMedix (CRMD) click here.

Form 8-K CorMedix Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26916530.html

Form 8-K CorMedix Inc. For: Aug 13

Thu, 13 Aug 2026 07:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26916530.html

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒

‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒

‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒

PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business.

Recent Corporate Highlights:

CorMedix announces $101.9 million of